Last reviewed · How we verify

NCT03429023

Descriptive Epidemiology on Management of Mucormycosis

Completed Last updated 12 February 2018
What this trial tests

trial in Mycoses in 500 participants. Completed in 30 September 2017.

Timeline
1 April 2016
Primary endpoint
30 September 2017
30 September 2017

Quick facts

Lead sponsorFungal Infection Study Forum
StatusCompleted
Study typeOBSERVATIONAL
Enrollment500
Start date1 April 2016
Primary completion30 September 2017
Estimated completion30 September 2017
Sites13 locations across India

Conditions studied

Sponsor

Fungal Infection Study Forum

Who can join

Adults 1 Day to 90, any sex, with Mycoses. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational chart review of all patients with confirmed and probable diagnosis of mucormycosis at 19 centers across Indian hospital. Data will collect using a standardized CRF. All collected data will be entered into a database prior to analysis. Broadly data will be collected on demography, clinical characteristics, diagnosis, treatment and outcome for each patient. Patient will continue to receive treatment as per treating physicians advise. Primary outcome for this study will be overall survival at 45 \& 90 days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03429023.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing